[{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Urology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase III","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Endeavor Health \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tizanidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Urology","graph2":"Phase III","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Endeavor Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Endeavor Health \/ Undisclosed"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nymox Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nymox Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nymox Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nymox Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nymox Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Canadian Urological Association","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase III","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Unity Health Toronto \/ Canadian Urological Association","highestDevelopmentStatusID":"10","companyTruncated":"Unity Health Toronto \/ Canadian Urological Association"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase III","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sumitomo \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo \/ Undisclosed"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Urovant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Urovant Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion Pharmaceuticals \/ Urovant Sciences"},{"orgOrder":0,"company":"Sumitovant Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vibegron","moa":"||Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase III","graph3":"Sumitovant Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitovant Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sumitovant Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Dongkook Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"DKF-313","moa":"Cholestenone-5-alpha-reductase","graph1":"Urology","graph2":"Phase III","graph3":"Dongkook Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dongkook Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dongkook Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Oxybutynin","moa":"Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3","graph1":"Urology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"DA-8010","moa":"Muscarinic receptor","graph1":"Urology","graph2":"Phase III","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Urology","graph2":"Phase III","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wake Forest University Health Sciences \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Wake Forest University Health Sciences \/ Merck & Co"},{"orgOrder":0,"company":"Vensica Therapeutics","sponsor":"Merz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"ISRAEL","productType":"Protein","year":"2022","type":"Partnership","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Urology","graph2":"Phase III","graph3":"Vensica Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Vensica Therapeutics \/ Merz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Vensica Therapeutics \/ Merz Pharma"},{"orgOrder":0,"company":"Dongkook Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dutasteride","moa":"||Steroid 5-alpha-reductase","graph1":"Urology","graph2":"Phase III","graph3":"Dongkook Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dongkook Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dongkook Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Provepharm Life Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"3,3\\'-Dioxo-2,2\\'-bisindolylidene-5,5\\'-disulfonate Disodium","moa":"Undisclosed","graph1":"Urology","graph2":"Phase III","graph3":"Provepharm Life Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Provepharm Life Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Provepharm Life Solutions \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"BRAZIL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DTT106","moa":"Undisclosed","graph1":"Urology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Huilun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"H077","moa":"Undisclosed","graph1":"Urology","graph2":"Phase III","graph3":"Shanghai Huilun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Huilun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Huilun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Intuitive Surgical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IS-001","moa":"Undisclosed","graph1":"Urology","graph2":"Phase III","graph3":"Intuitive Surgical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Intuitive Surgical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intuitive Surgical \/ Undisclosed"},{"orgOrder":0,"company":"Intuitive Surgical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IS-001","moa":"Undisclosed","graph1":"Urology","graph2":"Phase III","graph3":"Intuitive Surgical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Intuitive Surgical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intuitive Surgical \/ Undisclosed"},{"orgOrder":0,"company":"Jeil Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"JLP-2002","moa":"Undisclosed","graph1":"Urology","graph2":"Phase III","graph3":"Jeil Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jeil Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jeil Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"BRAZIL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"N0728","moa":"Undisclosed","graph1":"Urology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"SPP Pharmaclon Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Interferon gamma-1b","moa":"Undisclosed","graph1":"Urology","graph2":"Phase III","graph3":"SPP Pharmaclon Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SPP Pharmaclon Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SPP Pharmaclon Ltd. \/ Undisclosed"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : H077 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Prostatic Hyperplasia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 28, 2025

                          Lead Product(s) : H077

                          Therapeutic Area : Urology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : N0728 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prostatic Hyperplasia-associated with Lower Urinary Tract Symptoms.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 09, 2024

                          Lead Product(s) : N0728

                          Therapeutic Area : Urology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Nymozarfex (fexapotide triflutate) causes selective apoptosis in the glandular portions of the prostate. It is currently being investigated for benign prostate enlargement (BPH).

                          Product Name : Nymozarfex

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 16, 2024

                          Lead Product(s) : Fexapotide triflutate

                          Therapeutic Area : Urology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Indigotindisulfonate Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ureteral Injuries.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 07, 2024

                          Lead Product(s) : Indigo Carmine

                          Therapeutic Area : Urology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Gemtesa (vibegron) is a beta-3 adrenergic receptor agonist for treating male overactive bladder (OAB) with benign prostatic hyperplasia.

                          Product Name : Gemtesa

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 13, 2024

                          Lead Product(s) : Vibegron

                          Therapeutic Area : Urology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : DTT106 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prostatic Hyperplasia.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          February 20, 2024

                          Lead Product(s) : DTT106

                          Therapeutic Area : Urology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Endeavor Health

                          Country arrow
                          BioJapan
                          Not Confirmed

                          Endeavor Health

                          Country arrow
                          BioJapan
                          Not Confirmed

                          Details : Tizanidine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Postoperative Urinary Retention.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 14, 2024

                          Lead Product(s) : Tizanidine Hydrochloride

                          Therapeutic Area : Urology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : DKF-313 is a combination of dutasteride (5α-reductase inhibitor) and tadalafil (PDE5 inhibitor). It is being evaluated in phase 3 clinical trials for the treatment of benign prostatic hyperplasia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 26, 2023

                          Lead Product(s) : Dutasteride,Tadalafil

                          Therapeutic Area : Urology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Nymozarfex (fexapotide triflutate) causes selective apoptosis in the glandular portions of the prostate. It is currently being investigated for benign prostatic hyperplasia.

                          Product Name : Nymozarfex

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 25, 2023

                          Lead Product(s) : Fexapotide triflutate

                          Therapeutic Area : Urology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Gemtesa (vibegron) is a once-daily beta-3 adrenergic receptor (β3) agonist, is currently under investigation for the treatment of men with overactive bladder (OAB) symptoms receiving pharmacological therapy for benign prostatic hyperplasia.

                          Product Name : Gemtesa

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 11, 2023

                          Lead Product(s) : Vibegron

                          Therapeutic Area : Urology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank